A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-04-12
Adverse events
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-04-27 (study day 9); relationship: Y
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-05-13 (study day 25); relationship: N
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-11 (study day 237); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-27 (study day 315); relationship: N
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-07-18 (study day 456); relationship: not assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-10 (study day 479); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-10-16 (study day 546); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-12-03 (study day 594); relationship: Y
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-02-29 (study day 682); relationship: Y
Data queries
No data queries.